Date | Time | Source | Headline | Symbol | Company |
06/14/2024 | 6:07AM | iHub Newswire | FeaturedFifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates | | |
05/07/2024 | 7:00AM | GlobeNewswire Inc. | Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024 | NASDAQ:ORTX | Orchard Therapeutics PLC |
05/03/2024 | 7:00AM | GlobeNewswire Inc. | Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List | NASDAQ:ORTX | Orchard Therapeutics PLC |
03/20/2024 | 7:00AM | GlobeNewswire Inc. | Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy | NASDAQ:ORTX | Orchard Therapeutics PLC |
03/18/2024 | 3:41PM | GlobeNewswire Inc. | Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S. | NASDAQ:ORTX | Orchard Therapeutics PLC |
02/14/2024 | 9:05PM | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:ORTX | Orchard Therapeutics PLC |
02/05/2024 | 2:39PM | Edgar (US Regulatory) | Form 15-12G - Securities registration termination [Section 12(g)] | NASDAQ:ORTX | Orchard Therapeutics PLC |
02/05/2024 | 7:00AM | GlobeNewswire Inc. | Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome | NASDAQ:ORTX | Orchard Therapeutics PLC |
02/02/2024 | 7:00AM | GlobeNewswire Inc. | Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium | NASDAQ:ORTX | Orchard Therapeutics PLC |
01/31/2024 | 12:15AM | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:ORTX | Orchard Therapeutics PLC |
01/31/2024 | 12:15AM | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:ORTX | Orchard Therapeutics PLC |
01/25/2024 | 7:00AM | GlobeNewswire Inc. | Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy | NASDAQ:ORTX | Orchard Therapeutics PLC |
01/24/2024 | 5:20PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ORTX | Orchard Therapeutics PLC |
01/24/2024 | 5:18PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ORTX | Orchard Therapeutics PLC |
01/24/2024 | 5:17PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ORTX | Orchard Therapeutics PLC |
01/24/2024 | 4:41PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:ORTX | Orchard Therapeutics PLC |
01/24/2024 | 4:39PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:ORTX | Orchard Therapeutics PLC |
01/24/2024 | 4:37PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:ORTX | Orchard Therapeutics PLC |
01/24/2024 | 4:35PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:ORTX | Orchard Therapeutics PLC |
01/24/2024 | 4:34PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:ORTX | Orchard Therapeutics PLC |
01/24/2024 | 4:30PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:ORTX | Orchard Therapeutics PLC |
01/24/2024 | 4:28PM | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:ORTX | Orchard Therapeutics PLC |
01/24/2024 | 4:25PM | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:ORTX | Orchard Therapeutics PLC |
01/24/2024 | 4:17PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ORTX | Orchard Therapeutics PLC |
01/24/2024 | 5:00AM | GlobeNewswire Inc. | Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases | NASDAQ:ORTX | Orchard Therapeutics PLC |
01/22/2024 | 4:10PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ORTX | Orchard Therapeutics PLC |
12/19/2023 | 4:49PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ORTX | Orchard Therapeutics PLC |
12/11/2023 | 7:00AM | GlobeNewswire Inc. | Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD | NASDAQ:ORTX | Orchard Therapeutics PLC |
12/08/2023 | 4:39PM | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:ORTX | Orchard Therapeutics PLC |
12/08/2023 | 4:37PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ORTX | Orchard Therapeutics PLC |